1217486-93-5

Upstream product

• 1357476-67-5 4-bromo-2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridine 
• 1357476-66-4 2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4(1H)-one 
• 1357476-64-2 2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4H-pyran-4-one 
• 1163707-53-6 3,3,3-trifluoro-2,2-dimethylpropanoyl chloride 
• 889940-13-0 3,3,3-trifluoro-2,2-dimethylpropanoic acid 

Relevant academic research and scientific papers

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research. On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compounds in inhibiting PI3Kα, a medicinal chemistry program has led to the discovery of the clinical candidate NVP-BYL719.

ORGANIC COMPOUNDS

The present invention relates to a compound of formula (I) (I) or a salt thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.